newsfilter
← Latest News
GlobeNewswire·

Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week

MAZE
  • Maze Therapeutics will present seven scientific sessions at the American Society of Nephrology's Kidney Week in Houston from November 6-9, 2025.
  • The company will share updated pharmacokinetic data from the Phase 1 trial of MZE782, a novel oral SLC6A19 inhibitor.
  • MZE782 is positioned as a potential best-in-class therapy for phenylketonuria (PKU) and a first-in-class therapy for chronic kidney disease (CKD).
  • Preclinical research will be presented supporting SLC6A19 inhibition as a method to slow disease progression in CKD.
  • Maze will present data on MZE829, an oral APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD).
  • AMKD is a CKD subset estimated to affect over one million people in the United States.
  • The Phase 2 HORIZON trial for MZE829 is an open-label basket study enrolling patients with high-risk APOL1 alleles, including those with type 2 diabetes.
  • Maze expects the initial topline readout from the HORIZON trial in the first quarter of 2026.
  • Phase 1 data for MZE782 demonstrated an excellent safety profile, sustained urinary neutral amino acid excretion, and potential to improve kidney filtration.
  • Maze plans to advance MZE782 into Phase 2 studies for both PKU and CKD in 2026.
  • Seven specific presentation titles covering APOL1 variants, SLC6A19 functional mapping, and MZE782 safety were scheduled between November 6-8, 2025.
  • Maze Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California.